期刊文献+

影响消化道恶性肿瘤化疗患者继发口腔并发症的危险因素分析 被引量:2

下载PDF
导出
摘要 目的探讨消化道恶性肿瘤化疗患者继发口腔并发症的危险因素,为临床防治口腔并发症的出现提供参考。方法回顾性分析224例消化道恶性肿瘤接受化疗的患者的临床资料,对化疗后发生口腔并发症的可能危险因素进行分析。结果 224例化疗患者中,有84例发生口腔黏膜炎,发病率37.5%,口腔黏膜炎的发生部位主要为颊部(36.9%)、牙龈(23.8%),舌部(11.9%);多因素Logistic回归分析显示年龄(=1.443)、血清白蛋白水平<40g/L(=2.135)、白细胞降低程度(=2.015)、口腔自洁习惯坏(=1.143)、多个化疗周期(=1.847)、口腔p H值<6.5(=1.635)与消化道恶性肿瘤化疗患者继发口腔并发症密切相关。结论年龄、低血清白蛋白水平、白细胞降低程度、自身口腔自洁习惯、多个化疗周期及口腔p H值等多种因素导致消化道恶性肿瘤患者化疗后出现口腔并发症,应当积极加强感控措施,对各种危险因素进行干预以降低口腔黏膜炎的发生。
作者 张菡 蒋一玲
机构地区 浙江萧山医院
出处 《现代实用医学》 2015年第2期220-223,共4页 Modern Practical Medicine
  • 相关文献

参考文献13

  • 1Fukazawa M, Kawaguchi H, Shigematsu H, et al. High incideneerate of oral muco- sitis in breast cancer patients receiving an- thracycline-based chemotherapy (FEC 100)[J]. Cre To Kaonk'u Ryoho, 2012, 39(3) : 395-398.
  • 2Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral mucosi tis for patients with cancer receiving treat ment[J]. Cochrane Database Syst Rev, 2003,34(3) : 1231-1237.
  • 3Tsuyuki S, Kawaguchi K, Kawata Y, et al.Usefulness of antimycofic agents (ilraco- nazole) in chemotherapy-induced mucosi- tis of breast cancer patients[J]. Gan To Kagaku Ryoho, 2012, 39(9) : 1369-1373.
  • 4Nishimura N, Nakano K, Ueda K, et al. Prospective evaluation of incidence and severity of oral mucositis induced by con- ventional chemotherapy in solid tumors and malignant lymphomas [J]. Support Care Cancer, 2012, 20(9) : 2053-2059.
  • 5Cheng KK, Lee V, Li CH, et al. Oral mucositis in pediatric and adolescent pati- ents undergoing chemotherapy: the im- pact of symptoms on quality of life[J]. Sutroort Care Cancer. 2012. 20(10): 2335-2342.
  • 6冯华栋.放化疗所致口腔黏膜炎危险因素分析和护理干预[J].沈阳医学院学报,2011,13(1):39-42. 被引量:14
  • 7龚丽俐,顾艳荭,胡雁.放化疗性口腔黏膜炎发生情况及危险因素的研究进展[J].医学综述,2013,19(23):4315-4317. 被引量:21
  • 8薛松霞,张媛媛,曹选平.放化疗后口腔黏膜炎的研究进展[J].现代口腔医学杂志,2010,24(4):312-315. 被引量:13
  • 9高留节,丁纪元,张珍,黄建瑾.老年人非霍奇金淋巴瘤头颈部放疗口腔感染发生相关因素分析[J].中华老年医学杂志,2013,32(5):549-551. 被引量:11
  • 10Yen SH, Wang LW, Lin YH, et al. Phe- nylbutyrate mouthwash mitigates oral mu- cositis during radiotherapy or chemora-diotherapy in patients with head-and-neck cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 82(4) : 1463-1470.

二级参考文献73

  • 1Peterson DE. research advancce in oral mucositis. Curr Opin Oncol, 1999, 11(4) : 261 -266.
  • 2Lockhart PB, Sonis ST. Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol, 1979, 48 (1): 21-28.
  • 3Sonis ST. Mucositis as a biological process:a new hypothesis for the development of chemotherapy - induced sromatotoxicity. Oral Oncol, 1998, 34(1) : 39 -43.
  • 4Sonis ST, Peterson RL, Edwards LJ, et al. Defining mechanisms of action of interleukin - 11 on the progression of radiation - induced oral mucositis in hamsters. Oral Oncol, 2000, 36(4) : 373 -381.
  • 5Maj JG, Paris F, Haimovitz - Friedman A, et al. Microvascular function regulates intestinal crypt response to radiation. Cancer Res, 2003, 63:4338-4341.
  • 6Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol, 2007, 5(9) : 3 -11.
  • 7Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damageinmice. Science, 2001,293(5528) : 293 -297.
  • 8Sonis ST. A biological approach to mueositis. J Support Oncol, 2004, 2(1): 21 -36.
  • 9Biswa Mohan Biswal. current trends in the management of oral mucositis related to cancer treatment. Malaysian Journal of Medical Sciences, 2008, 15(3) : 4 -13.
  • 10Redding SW. Cancer therapy - related oral mucositis..Journal of Dental Education, 2005, 69(8) : 919 -929.

共引文献60

同被引文献22

引证文献2

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部